Epidermolysis Bullosa, Pipeline Review, H2 2019 – Almirall SA, Berg LLC, Celularity Inc, CSL Ltd & Constant Therapeutics LLC – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Epidermolysis Bullosa – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 13, 2, 2, 16, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Epidermolysis Bullosa – Overview
• Epidermolysis Bullosa – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Epidermolysis Bullosa – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Epidermolysis Bullosa – Companies Involved in Therapeutics Development
• Abeona Therapeutics Inc
• Aegle Therapeutics Corp
• Almirall SA
• Amryt Pharma Plc
• Anterogen Co Ltd
• APR Applied Pharma Research SA
• Berg LLC
• BioVec Pharma Inc
• BridgeBio Pharma Inc
• Castle Creek Pharmaceuticals LLC
• Celularity Inc
• Constant Therapeutics LLC
• CSA Biotechnologies LLC
• CSL Ltd
• Daewoong Pharmaceutical Co Ltd
• Ember Therapeutics Inc (Inactive)
• FIBRX Derm Inc
• GlaxoSmithKline Plc
• Holostem Terapie Avanzate Srl
• Immusoft Corp
• InMed Pharmaceuticals Inc
• Krystal Biotech Inc
• LambdaGen Therapeutics
• Mesoblast Ltd
• OTR3 SAS
• Palvella Therapeutics LLC
• Phoenix Tissue Repair Inc
• Quoin Pharmaceuticals Ltd
• RegeneRx Biopharmaceuticals Inc
• RHEACELL GmbH & Co KG
• Shionogi & Co Ltd
• StemRIM Inc
• Therapicon Srl
• Trucode Gene Repair Inc
• TWi Biotechnology Inc
• Wings Therapeutics
• Epidermolysis Bullosa – Drug Profiles
• Epidermolysis Bullosa – Dormant Projects
• Epidermolysis Bullosa – Discontinued Products
• Epidermolysis Bullosa – Product Development Milestones
• Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ndhyod

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900